Interim results of Phase 3 clinical studies investigating two major challenges in hemophilia — the development of inhibitors (antibodies to the drug used to treat bleeding episodes) and the need for repeated venous injection of blood clotting protein Factor VIII (FVIII) — were recently released. The results were presented by…
Search results for:
Creating personalized hemophilia B care is an important part of hemophilia B management.Your healthcare team can set up a treatment plan based on your specific needs and the severity of your symptoms.
Social Clips
Living With Hemophilia: Ryan’s Story
https://www.youtube.com/watch?v=IhVOXnB-0KQ In this video from Bleeding Disorders Community, Ryan shares his hemophilia story. He was diagnosed as a baby with severe hemophilia but he doesn’t let the disease stand in the way of his passion for fitness. MORE: Improvement in gene therapy carriers key step in hemophilia…
News
Researchers Develop Faster, Less Expensive, Non-invasive Method for Hemophilia A Prenatal Diagnosis
Researchers have developed a faster, less expensive, reliable method for non-invasive prenatal diagnosis (NIPD) of hemophilia A. Future, larger studies are required to confirm the utility of the method, which could be used for the NIPD of hemophilia A and type B, as well as other X-linked…
The National Institutes of Health (NIH) is supporting a university’s research into the risk factors and underlying mechanisms involved in the development of neutralizing antibodies, or inhibitors, against replacement therapies in people with hemophilia A. The $6.6 million, three-year grant from the NIH’s National Heart, Lung, and Blood Institute…
Well over 70% of children with severe hemophilia born in a region of Italy in the last 20 years were to women without a family history of the disease, data from a registry analysis show. “Our data highlight the importance of genetic counselling, especially in families with apparently sporadic haemophilia cases,…
News
Age at Start of Therapy in Advanced Hemophilia Patients Determines Improvements in Joint Motion
Therapy to prevent bleeding (called prophylaxis) in patients with severe hemophilia A led to decreased joint bleeding when it was started at any age. However, improved joint motion was only effective if prophylaxis was started before age 4 in non-obese patients, according to researchers. The study, “Prophylaxis Usage, Bleeding…
Altuviiio (efanesoctocog alfa) is an approved long-lasting factor VIII (FVIII) replacement therapy used to reduce the frequency of bleeding episodes or control and manage active bleeds, including those occurring during surgery, in children and adults with hemophilia A.
Our baby girl turned one earlier this year. Watching Cittie mature makes me reflect on the innocent phase of childhood. Life was so simple back then. I believed games and toys to be major issues of the utmost importance. I stayed late after school and played with my friends.